Lonaprisan

DB16221InvestigationalSmall molecule

Lonaprisan is under investigation in clinical trial NCT00555919 (ZK 230211 in Postmenopausal Woman With Metastatic Breast Cancer).

Mechanism: Pharmacologically active on Progesterone receptor
Curator reviewed
Formula / weight: C₂₈H₂₉F₅O₃ · 508.529 g/mol (avg)
Code names: BAY86-5044 · ZK-230211

Resolves to

Compound

UNIIF5Z5EL4D26CAS211254-73-8ChEMBLCHEMBL146032

Structure

InChIKeyVHZPUDNSVGRVMB-RXDLHWJPSA-NSMILES[H][C@@]12CC[C@@](O)(C(F)(F)C(F)(F)F)[C@@]1(C)C[C@H](C1=CC=C(C=C1)C(C)=O)C1=C3CCC(=O)C=C3CC[C@@]21[H]

Targets

P06401PGRP10275AR P04150NR3C1

What you can answer from here — as of June 15, 2026

3Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

9+ReferencesStructured and connected to the statements they support

Which drugs share a target with Lonaprisan, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account